İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2022 · article

The impact of COVID-19 pandemic on psoriasis patients, and their immunosuppressive treatment: a cross-sectional multicenter study from Turkey

YÖKSİS OpenAlex
Yıl2022
Atıf19OpenAlex
Atıf20Semantic Scholar · 1 etkili
Yüzdelik%78,4
FWCI1,261,00 = dünya ortalaması
Scopus (SJR)Q1
WoS (JCR)Q2

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıJournal of Dermatological Treatment
  • Katalog eşleşmesi (ISSN)Journal of Dermatological Treatment
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

Background Immunosuppressive therapy has been a great concern during the pandemic. This study aimed to evaluate the pandemic's impact on psoriasis patients treated with immunosuppressive drugs.Material and Methods The multicenter study was conducted in 14 tertiary dermatology centers. Demographic data, treatment status, disease course, and cases of COVID-19 were evaluated in patients with psoriasis using the immunosuppressive treatment.Results Of 1827 patients included, the drug adherence rate was 68.2%. Those receiving anti-interleukin (anti-IL) drugs were more likely to continue treatment than patients receiving conventional drugs (OR = 1.50, 95% CI, 1.181–1.895, p = .001). Disease worsening rate was 24.2% and drug dose reduction increased this rate 3.26 and drug withdrawal 8.71 times. Receiving anti-TNF or anti-IL drugs was associated with less disease worsening compared to conventional drugs (p = .038, p = .032; respectively). Drug withdrawal causes were ‘unable to come’ (39.6%), ‘COVID concern’ (25.3%), and ‘physician’s and patient’s co-decision’ (17.4%). Four patients had COVID-19 infection with mild symptoms. The incidence was 0.0022% while it was 0.0025% in the general population.Conclusion Our study shows that psoriasis patients using systemic immunosuppressive do not have a higher, but even lower COVID-19 risk than the general population, and treatment compliance with biological drugs is higher.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

19atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yerel katalogda bu makaleye atıf yapan 2 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).

  1. 2023 Clinical course of psoriasis patients that discontinued biologics during the COVID ‐19 pandemicAtıf 8 · OpenAlex
  2. 2023 Clinical course of psoriasis patients that discontinued biologics during the COVID‐19 pandemicAtıf 8 · OpenAlex

Yazarlar

28
  1. SELDA PELİN KARTAL 1
  2. GÖKÇEN ÇELİK ÖZBAHÇE 2
  3. OĞUZ YILMAZ 3
  4. EDA ÖKSÜM SOLAK 4
  5. BÜŞRA DEMİRBAĞ GÜL 5
  6. TUBA KEVSER ÜSTÜNBAŞ 6
  7. MELİS GÖNÜLAL 7
  8. SEVİM BAYSAK 8
  9. ESMA İNAN YÜKSEL 9
  10. MÜNEVVER GÜVEN 10
  11. ALİ BOZDAĞ 11
  12. GÖKHAN ÇINAR 12
  13. SELİM KARTAL 13
  14. MURAT BORLU 14
  15. MÜGE GÜLER ÖZDEN 15
  16. BURHAN ENGİN 16
  17. SERVER SERDAROĞLU 17
  18. DİDEM DİDAR BALCI 18
  19. BİLAL DOĞAN 19
  20. DEMET ÇİÇEK 20
  21. ayça cordan yazıcı 21
  22. SEMA AYTEKİN TEKİRDAĞ NAMIK KEMAL ÜNİVERSİTESİ 22
  23. NESLİHAN ŞENDUR 23
  24. HAYRİYE SARICAOĞLU 24
  25. NİDA GELİNCİK 25
  26. ASENA ÇİĞDEM DOĞRAMACI HATAY MUSTAFA KEMAL ÜNİVERSİTESİ 26
  27. LEVENT DÖNMEZ 27
  28. ERKAN ALPSOY 28